ClinicalTrials.Veeva
Menu

A Study to Assess the Efficacy of GX-03 in Moderate to Severe Eczema (Atopic Dermatitis) (GX-03 in AD)

T

Turn Therapeutics

Status and phase

Enrolling
Phase 2

Conditions

Atopic Dermatitis
Eczema Atopic Dermatitis
Eczema

Treatments

Combination Product: GX-03
Other: Vehicle

Study type

Interventional

Funder types

Industry

Identifiers

NCT07355075
Protocol/Panel 4604

Details and patient eligibility

About

This is a randomized, double-blind, vehicle-controlled clinical study designed to evaluate the efficacy and safety of GX-03, a topically applied emollient, in adult subjects with moderate to severe eczema. Approximately 120 adult participants will be enrolled and randomized in a 1:1 ratio to receive either GX-03 or a petrolatum-based vehicle control for 8 consecutive weeks. Efficacy will be assessed using validated clinical outcome measures, including the Eczema Area and Severity Index (EASI), the Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™), and the Peak Pruritus Numeric Rating Scale (PP-NRS). Safety will be evaluated through monitoring of treatment-emergent adverse events throughout the study period.

Full description

This Phase 2, randomized, double-blind, vehicle-controlled study will assess the efficacy and safety of GX-03 in adult individuals aged 18 to 70 years with moderate to severe eczema. Eligible participants will be randomly assigned to receive either GX-03 or a vehicle control, applied topically to affected areas at least twice daily for 8 weeks. The investigational product and vehicle will be identical in appearance and packaging to maintain blinding.

Clinical efficacy will be evaluated at baseline and at Weeks 4 and 8. The primary efficacy endpoint is the change from baseline in Eczema Area and Severity Index (EASI) score at Weeks 4 and 8. Secondary efficacy endpoints include changes from baseline in vIGA-AD™ scores and Peak Pruritus Numeric Rating Scale (PP-NRS) scores at the same time points. Subject-reported outcomes and product preference questionnaires will also be collected as exploratory measures.

Safety assessments will include the collection of spontaneous and solicited adverse events from the first application through the final study visit. Weekly telephone safety check-ins will be conducted during interim weeks, and adverse events will be assessed at all on-site visits. The study is expected to enroll sufficient subjects to ensure that at least 100 participants complete the full 8-week treatment period.

Read more

Enrollment

100 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Participants must meet all of the following criteria:

  • Adults aged 18 to 70 years, inclusive
  • Male or female subjects in good general health as determined by medical history
  • Presence of visible eczematous skin with disease severity consistent with moderate to severe eczema, as assessed by:
  • Eczema Area and Severity Index (EASI) and
  • Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™)
  • Ability to read, understand, and provide written informed consent in English
  • Willingness and ability to comply with study procedures, including study visits and daily topical application
  • Agreement to use only the assigned study product on designated areas of interest for the duration of the study

Exclusion Criteria

Individuals meeting any of the following criteria will be excluded:

  • Pregnant, breastfeeding, or planning pregnancy during the study
  • Presence of any skin condition or dermatologic disease that could interfere with study treatment or assessments
  • Use of systemic or topical immunosuppressive therapies, including corticosteroids, within 3 weeks prior to enrollment
  • Use of anti-inflammatory medications (e.g., topical steroids, ibuprofen, celecoxib); steroid nasal or ophthalmic drops are permitted
  • Use of topical medications at the test sites within 72 hours prior to enrollment
  • Damaged or altered skin at or near test sites (e.g., sunburn, tattoos, scars, uneven pigmentation) that could confound evaluations
  • Any medical condition that, in the investigator's judgment, places the subject at undue risk or compromises study integrity

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

100 participants in 2 patient groups, including a placebo group

GX-03
Experimental group
Description:
Treatment Arm
Treatment:
Combination Product: GX-03
Vehicle
Placebo Comparator group
Description:
Vehicle Control
Treatment:
Other: Vehicle

Trial contacts and locations

1

Loading...

Central trial contact

Barry Reece, MS

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems